文献速递糖尿病肥胖与代谢综合征

糖尿病前期缓解与心血管发病率和死亡率:DPPOS与DaQingDPOS事后分析

Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-12-12

基于美国DPPOS和中国大庆糖尿病预防结局研究的事后分析,评估糖尿病前期缓解(按ADA标准)与心血管死亡或心衰住院的长期关联。

要点

  • 糖尿病前期缓解与心血管死亡或心衰住院风险降低约一半相关,获益持续数十年。

核心结论

  • 达到糖尿病前期缓解与心血管死亡或心衰住院风险降低约一半相关,且具有长期遗留效应。
  • 以缓解为目标的干预可能成为心血管预防的新策略。

研究设计与样本

  • 对DPPOS和DaQingDPOS两项里程碑式糖尿病预防试验进行事后分析。
  • DPPOS在干预1年后、DaQingDPOS在干预6年后按ADA标准评估缓解。
  • DPPOS纳入2402例,DaQingDPOS纳入540例。
  • DPPOS主要终点为20年内心血管死亡或心衰住院,DaQingDPOS为30年。
  • DPPOS采用逆概率治疗加权校正基线差异,并汇总两数据集进行meta分析。

关键数值与推荐

  • 缓解采用美国糖尿病协会(ADA)标准评估。
  • DPPOS在干预1年后评估缓解,DaQingDPOS在干预6年后评估。
  • 主要终点为心血管死亡或心衰住院。

临床怎么用

  • 对糖尿病前期人群,生活方式干预应以恢复正常糖调节(缓解)为重要目标。
  • 达到糖尿病前期缓解可作为心血管风险长期降低的评估指标。

局限性

  • 为事后分析,非预设随机比较。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prediabetes is associated with increased risk of cardiovascular disease and heart failure. Multicomponent lifestyle interventions, including diet and physical activity targeting weight loss are recommended for prediabetes management, although their long-term impact on cardiovascular outcomes remains unclear. Reaching prediabetes remission by restoring normal glucose regulation has been shown to profoundly reduce future type 2 diabetes risk outlasting the time of lifestyle intervention. We aimed to investigate whether prediabetes remission is associated with a lower incidence of cardiovascular death or hospitalisation for heart failure compared with non-remission, with a long-term legacy effect. METHODS: Post-hoc analyses were performed from two landmark diabetes prevention trials, the US Diabetes Prevention Program Outcomes Study (DPPOS) and the Chinese DaQing Diabetes Prevention Outcomes Study (DaQingDPOS). Remission was assessed using the American Diabetes Association criteria after 1 year (DPPOS) or 6 years (DaQingDPOS) of intervention. The primary endpoint was cardiovascular death or hospitalisation for heart failure over 20 and 30 years, respectively. In DPPOS, inverse probability of treatment weighting adjusted for baseline differences. A unifying meta-analysis was calculated across both data sets for the primary endpoint and all-cause mortality. FINDINGS: For DPPOS, follow-up time is reported from the start of the original Diabetes Prevention Program trial, July 31, 1996, to the end of DPPOS phase 3, Feb 23, 2020. In total, 2402 participants were included in DPPOS and 540 in DaQingDPOS. In DPPOS, 275 (11·5%) of 2402 participants reached remission after 1 year of intervention compared with 2127 (88·5%) of 2402 not reaching remission. In DPPOS, after a median follow-up of 20 years, the event rate for cardiovascular death or hospitalisation of heart failure was 1·74 (95% CI 0·87-3·48) per 1000 person-years in participants who reached remission versus 4·17 (95% CI 3·55-4·89) in those without remission (p=0·013) with a fully adjusted hazard ratio of 0·41 (95% CI 0·20-0·84; p=0·014). Results remained robust after adjustment, were confirmed in DaQingDPOS (primary endpoint: HR 0·49 [95% CI 0·28-0·84]; p=0·010), and were supported by a pooled meta-analysis. Results were stable when analysing the composite endpoint in those reaching remission at least once during follow-up, with a HR of 0·43 (0·29-0·63; p<0·0001). INTERPRETATION: Reaching prediatbetes remission is linked to a decades-long benefit, halving the risk of cardiovascular death or hospitalisation for heart failure in diverse populations. Targeting remission might represent a new approach to cardiovascular prevention. FUNDING: German Center for Diabetes Research via the German Federal Ministry of Research, Technology and Space; Ministry of Science, Research, and the Arts Baden-Württemberg; Helmholtz Munich; the Helmholtz Young Investigators Groups funding programme; the Cluster of Excellence EXC-2124; and the German Research Foundation (DFG). For DaQing: Centers for Disease Control and Prevention, WHO, the China-Japan Friendship Hospital, and Da Qing First Hospital and Fuwai Hospital, Chinese Academy of Medical Sciences. For DPPOS: National Institute of Diabetes and Digestive and Kidney Diseases. TRANSLATIONS: For the German and Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Vazquez Arreola E, Gong Q, Hanson RL, et al. Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study. Lancet Diabetes Endocrinol. 2025. PMID: 41397402. doi:10.1016/S2213-8587(25)00295-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。